Positioning of DPP-4 Inhibitors in the Treatment Algorithm of type 2 Diabetes In 2018 the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a new joint position statement for the treatment of type 2 diabetes ( If therapeutic goals are not met with these measures, certain patient characteristics determine the further recommended treatment options
(2017b)
At the very least, we wouldve been looking at more cuts in staffing and increases in class sizes to afford nearly 20% increases in health care costs
Pack Size & Treatment Yield
Phase I and II clinical trials conducted have shown improved cognitive and motor function with different drugs from GLP-1RA group although the small sized and limited duration of trials have not provided a conclusive result to influence the practice, although with further advancement in ongoing trials effects observed may be noteworthy for intervention in future practice (119)
However, reports published on Scopus, PubMed, and Web of Science were studied which gives us important information that TMAO, the gut metabolite, is not only involved in causing atherosclerosis but its high levels in the blood can be a serious threat to human life due to its association with various other ailments